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Peptide–membrane interactionsLactoferricin and lactoferrampin are two antimicrobial peptides found in the N-terminal lobe of bovine lacto-
ferrin with broad spectrum antimicrobial activity against a range of Gram-positive and Gram-negative bacte-
ria as well as Candida albicans. A heterodimer comprised of lactoferrampin joined to a fragment of lactoferricin
was recently reported in which these two peptides were joined at their C-termini through the two amino
groups of a single Lys residue (Bolscher et al., 2009, Biochimie 91(1):123–132). This hybrid peptide, termed
LFchimera, has signiﬁcantly higher antimicrobial activity compared to the individual peptides or an equimolar
mixture of the two. In this work, the underlying mechanism behind the increased antibacterial activity of
LFchimera was investigated. Differential scanning calorimetry studies demonstrated that all the peptides
inﬂuenced the thermotropic phase behaviour of anionic phospholipid suspensions. Calcein leakage and vesicle
fusion experiments with anionic liposomes revealed that LFchimera had enhanced membrane perturbing
properties compared to the individual peptides. Peptide structures were evaluated using circular dichroism
andNMR spectroscopy to gain insight into the structural features of LFchimera that contribute to the increased
antimicrobial activity. The NMR solution structure, determined in amiscible co-solvent mixture of chloroform,
methanol and water, revealed that the Lys linkage increased the helical content in LFchimera compared to the
individual peptides, but it did not ﬁx the relative orientations of lactoferricin and lactoferrampin with respect
to each other. The structure of LFchimera provides insight into the conformation of this peptide in a membra-
nous environment and improves our understanding of its antimicrobial mechanism of action.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
The majority of biophysical studies concerning antimicrobial pep-
tides published to date focus on a variety of experiments performed
on highly puriﬁed peptide samples in an effort to characterize the an-
timicrobial mode of action of a single peptide [1]. A recent trend has
seen the emergence of reports that focus on the combined effects of
antimicrobial peptides wherein a mixture of peptides, administered
together, cause a more substantial antimicrobial effect [2–4]. The con-
cept of synergy between antimicrobial peptides is rapidly gaining
momentum as researchers seek to enhance the antimicrobial activityG, 1,2-dihexadecanoyl-sn-gly-
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l rights reserved.and effectiveness of peptide sequences [5]. The combined effect of
multiple antimicrobial peptides has inspired the generation of unique
hybrid antimicrobial peptides in which peptides are covalently linked
to each other to generate molecules with enhanced antimicrobial ac-
tivity. An example of such a hybrid peptide is the disulphide-linked
magainin-PGLa heterodimer [6] for which we recently published the
micelle bound structure [7]. In the present work, the structure and
membrane perturbing properties of a novel hybrid peptide comprised
of two antimicrobial sequences obtained from the intact bovine lacto-
ferrin protein is evaluated and compared to each of the component
peptides. A unique feature of this peptide chimera is that the two
peptides are covalently joined at their C-termini through the two
amino groups of a single lysine residue.
Lactoferrin is an 80 kDa iron binding protein found in the secretory
ﬂuids of mammals. In addition to its well-documented ability to bind
iron, which contributes directly to its antibacterial properties by seques-
tering iron required for bacterial growth [8, 9], lactoferrin also possesses
a wide range of biological functions (unrelated to iron binding) includ-
ing antibacterial, antiviral, anticancer and immunomodulatory activities
[10–12]. Of particular interest to antimicrobial peptide researchers is the
cationic N-terminal lobe of bovine lactoferrin which includes two anti-
microbial sequences, lactoferricin and lactoferrampin (Fig. 1).
Fig. 1. Crystal structure of bovine lactoferrin (PDB ID=1BLF, A). Each lobe of lactoferrin
is capable of binding to one iron atom, shown in red. Bovine lactoferrin is the source of
two antimicrobial peptides, lactoferricin and lactoferrampin. LFcin17–30 (blue) and
LFampB (green) are found in the highly cationic N-terminal lobe of bovine lactoferrin
as seen in the space ﬁlling model of the protein with positively charged regions
coloured in blue, negatively charged regions in red and neutral regions appearing
white. The sequences of the two peptides, as well as the unique sequence of LFchimera,
in which the two peptides are joined through a single Lys residue, are shown in (B).
Joining these two peptides through a single lysine residue makes it possible for these
sequences to maintain a relative orientation with respect to each other, similar to
that seen in the crystal structure of bovine lactoferrin.
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extensively studied by several groups, including our own. LFcins
are released from lactoferrin by the proteolytic activity of pepsin
in the gut [13–15]. These polypeptides display signiﬁcantly higher
antibacterial activity compared to the intact lactoferrin protein and
considerable effort has gone into elucidating their mechanism of ac-
tion [16]. Bovine LFcin corresponds to residues 17–41 of lactoferrin
and it forms an amphipathic β-sheet hairpin structure in aqueous
solution [17] that is distinct from the α-helical conformation seen
in the corresponding sequence in the crystal structure of bovine lac-
toferrin [18]. Shorter versions of bovine LFcin retain much of the an-
timicrobial activity of the native peptide and these truncated forms
have provided detailed structural, functional and biophysical in-
sights into the interaction between LFcin and lipid bilayers or bacte-
rial cells [19–24].
Bovine lactoferrampin (LFampB) is an antimicrobial peptide iden-
tiﬁed through sequence analysis of bovine lactoferrin [24] with broad
range antimicrobial activity against a variety of Gram-positive and
Gram-negative bacteria as well as candidacidal activity [25–28].
Freeze-fracture transmission electron microscopy of E. coli and C. albi-
cans cells treated with LFampB revealed that the peptide causes par-
tial disintegration of the plasma membrane [29], suggesting that the
primary target of lactoferrampin is the cytoplasmic membrane.
The solution structures and membrane interactions of bovine and
human lactoferrampins have been extensively characterized [30–32].
Like many antimicrobial peptides, lactoferrampin is unstructured in
aqueous solution and it only adopts a helical conformation in the
presence of lipids. The sodium dodecyl sulphate (SDS) micelle-bound NMR solution structure of lactoferrampin revealed an amphi-
pathic helix in the N-terminal region of the peptide, while the cationic
C-terminal region is devoid of regular secondary structure. Interest-
ingly, removal of the positive charges in the C-terminal region de-
creases the antimicrobial potency of the peptide [26, 28] and adding
positive charges to this region increases the antimicrobial activity
[32]. Based on these results, a model of antimicrobial activity has
been described wherein the cationic C-terminal region mediates the
initial attraction of lactoferrampin to the negatively charged bacterial
surface. This electrostatic attraction brings lactoferrampin into close
proximity to the bacterial membrane, allowing for folding and inser-
tion of the N-terminal helix into the bilayer, ultimately leading to
membrane perturbation and cell death.
In the present work, the antimicrobial mechanism of action of a
unique hybrid antimicrobial peptide composed of LFampB and
LFcin17–30 is examined. The heterodimeric peptide (named LFchi-
mera) is coupled together through the two amino groups of a single
lysine residue at the C-terminal ends of both constituent peptides.
In addition, the carboxyl group on the lysine linker is amidated to re-
move the negative charge (Fig. 1B). The rationale behind the design of
the LFchimera was to link these two peptides in a manner that could
maintain their relative orientation as seen in the crystal structure of
bovine lactoferrin [18]. Since many of the biological host-defence ac-
tivities of lactoferrin are localized in the cationic N-terminal lobe of
the protein, it was hypothesized that joining LFampB to LFcin through
this Lys linker might maintain the spatial orientation of these two se-
quences and enhance the activity of this heterodimer. Indeed, exten-
sive characterization of the activity of LFchimera has shown it to be
remarkably more potent against Gram-positive and Gram-negative
bacteria compared to either of the constituent peptides [33, 34]. Addi-
tionally, the LFchimera has been found to possess antiparasitic activ-
ity [35] and even antibiotic resistant strains of Staphylococcus aureus
and Escherichia coli are susceptible to this hybrid peptide [36]. To-
gether, these studies highlight the potential of LFchimera as a future
treatment option for serious bacterial infections. However, the struc-
ture of LFchimera and the molecular mechanisms underlying the en-
hanced antimicrobial activity remain to be elucidated.
In the present work, the effect of the peptides on the thermotropic
phase behaviour of anionic phospholipids was examined using differ-
ential scanning calorimetry (DSC) [37]. Furthermore, the membrane
perturbing properties of LFchimera and its constituent peptides was
evaluated by monitoring the release of the self quenching dye, cal-
cein, from large unilamellar vesicles (LUVs) of varying lipid composi-
tion. Peptide induced liposome fusion was also assessed as this is a
feature that has previously been reported for the full length bovine
LFcin peptide [38]. Structural characterization of all the peptides
was performed using circular dichroism (CD) spectroscopy and high
resolution nuclear magnetic resonance (NMR) spectroscopy. The re-
sults presented here reveal that the LFchimera has a stronger mem-
brane perturbing effect than either LFampB or LFcin17–30 or a
mixture of these two peptides. The CD and NMR structural results
demonstrate that the LFchimera has increased helical content com-
pared to the two constituent peptides, suggesting that the Lys linkage
inﬂuences the structure of the LFampB and LFcin17–30 regions of
LFchimera. The outcome of these experiments is discussed with re-
spect to the previously reported antimicrobial activity of LFampB,
LFcin17–30 and LFchimera. In addition, the merits of using a co-
solvent mixture as a mimic for biological membranes in NMR spec-
troscopy are also considered.
2. Methods and materials
2.1. Peptide synthesis
Synthesis of LFcin17–30 and LFampB was performed in the same
manner as described previously [29, 32]. The synthesis of LFchimera
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special precursors from NovaBiochem (Now EMD Chemicals, Gibbs-
town, NJ). Brieﬂy, synthesis was started by coupling Fmoc-
Lys(ivDde)-OH to NovaSyn®TGR resin followed by the synthesis of
LFcin17–30, terminated with N-α-t-BOC-protected Phe. Next, the
ivDde-protecting group on the C-terminal Lys side chain was released
by hydrazinolysis followed by the synthesis of LFampB. In this man-
ner the LFchimera peptide comprises a single C-terminal lysine-
amide substituted at the α- and ε-amino groups with the two pep-
tides via the C-terminal site, while leaving the two N-termini as free
ends. All peptides were puriﬁed with RP-HPLC (Jasco Inc. Easton,
MD) to at least 95% purity and their identity was conﬁrmed with
ion trap mass spectrometry.
2.2. Preparation of lipid vesicles
Stock chloroform lipid solutions of egg derived phosphatidylgly-
cerol (ePG), egg phosphatidylethanolamine (ePE) and E. coli polar
lipid extract (PLE) were obtained from Avanti Polar Lipids (Alabaster,
AL). Brieﬂy, the necessary volume of stock lipid solution was added to
a glass vial and the chloroform solvent was evaporated in a stream of
nitrogen gas. The vial was then placed under vacuum for ~2 h to re-
move all traces of the organic solvent. Large unilamellar vesicles
(LUVs) composed of 3:1 and 1:1 ratios of ePE:ePG as well as PLE
were prepared according to Schibli et al., [39]. To prepare calcein en-
capsulated LUVs, the dried lipid ﬁlm was resuspended in Tris buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4) containing 70 mM
calcein. The lipid suspension was freeze-thawed ﬁve times using liq-
uid nitrogen followed by 15 passes through two 0.1 μmpolycarbonate
ﬁlters (Nucleopore Filtration Products, Pleasonton, CA) using a mini-
extruder apparatus (Avanti Polar Lipids, Alabaster, AL) to generate
LUVs. The calcein containing LUVs were separated from free calcein
using a Sephadex G-50 superﬁne gel-ﬁltration column. Calcein encap-
sulated LUVs were visually collected as the ﬁrst strong yellow fraction
to elute from the column. Liposomes used in the fusion assays were
prepared by sonicating the lipid suspension for ~1 h until the lipid
suspension clariﬁed. The concentration of lipid in all the samples
was determined using the Ames phosphate assay [40], performed in
triplicate.
2.3. Differential scanning calorimetry
The effect of the peptides on the thermotropic phase behaviour of
1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG,
Avanti Polar Lipids, Alabaster, AL) phospholipids was examined
using differential scanning calorimetry (DSC) according to a modiﬁed
protocol described by Prenner et al. [41]. Brieﬂy, a 1 mg lipid ﬁlm was
prepared in a glass vial by evaporating the organic solvent from an
appropriate volume of a chloroform stock solution of DPPG under a
stream of nitrogen gas. The vial was incubated under vacuum for
~2 h and then stored at−20 °C until needed. The lipid ﬁlm was heat-
ed to 60 °C and warm Tris buffer (10 mM Tris, 150 mM NaCl, 1 mM
EDTA, pH 7.4) was added, followed by vigorous vortexing to resus-
pend all the lipid. Aqueous peptide solutions of LFcin17–30, LFampB
and LFchimera were added to the lipid suspensions to achieve
molar peptide:lipid ratios of 1:100, 1:50 and 1:10. The ﬁnal concen-
tration of DPPG in each DSC sample was 1.0 mg/ml.
The DSC experiments were carried out on degassed lipid samples
using a Microcal high sensitivity VP-DSC (GE Healthcare, Piscatawy,
NJ). Five heating scans between 20 and 60 °C were recorded for
each sample using a scan rate of 10 °C/h. In all cases, the fourth and
ﬁfth heating scans were identical, indicating that the peptide had
equilibrated amongst the lipid molecules. The ﬁfth heating scan was
used in the ﬁnal analysis, performed with the Microcal Origin Soft-
ware (version 7.0).2.4. Calcein leakage
Calcein release from calcein encapsulated LUVs was monitored
using a Varian Cary Eclipse Fluorimeter (Varian Inc. Palo Alto, CA.).
Calcein containing LUVs were added to a ﬁnal lipid concentration of
10 μM and the ﬂuorescence intensity at 520 nm (excitation 490 nm)
was measured for 1 min. After 1 min, the peptide was added to a
ﬁnal concentration of 1 μM (peptide:lipid ratio of 1:10) and the ﬂuo-
rescence emission was monitored for 10 min. At this point, 20 μl of 1%
Triton X-100 was added to solubilise all of the LUVs and the ﬂuores-
cence was monitored for another 1.5 min. Peptide to lipid molar ra-
tios of 1:20, 1:30, 1:50 and 1:100 were tested by adjusting the
amount of peptide added to the calcein LUV solutions. Solutions of
LFampB, LFcin17–30, LFchimera and a mixture of the two constituent
peptides were evaluated for their ability to induce calcein leakage.
The % leakage of calcein was calculated using the following equation:
%leakage ¼ 100 I−Ioð Þ= It−Ioð Þ
where I is the ﬂuorescence intensity 10 min after the addition of pep-
tide, Io is the ﬂuorescence intensity prior to the addition of peptide
and It is the intensity after the addition of triton. All calcein leakage
experiments were performed in triplicate.
2.5. Liposome fusion
Peptide induced fusion of liposomes was examined by monitoring
the change in absorbance of a peptide and liposome solution at
400 nm. An increase in the absorbance value at 400 nm is indicative
of vesicle fusion [38, 42]. The absorbance of an ePE:ePG liposome so-
lution (lipid concentration of 0.1 mM) was measured after 15 min of
incubation with each peptide. Molar peptide to lipid ratios of 1:100,
1:50, 1:20 and 1:10 were tested and the experiments were performed
in triplicate. In addition, the particle size of these same liposome solu-
tions were monitored using a DynaPro dynamic light scattering in-
strument (Wyatt Technology Corporation, Santa Barbara, CA) to
conﬁrm the results of the liposome fusion assay (data not shown).
2.6. Circular dichroism spectroscopy
Circular dichroism spectra were acquired on a Jasco J-810 spectro-
polarimeter (Jasco, Inc. Easton, MD). 50 μM peptide samples in buffer
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4) and in buffered
200 mM SDS were collected at room temperature between 190 and
260 nm using a 1 mm pathlength cuvette. Additional samples con-
taining a mixture of LFcin17–30 and LFampB, each at a concentration
of 50 μM, were also recorded under the same conditions. Ellipticity
values were recorded every 0.1 nm at a wavelength scanning speed
of 200 nm/min. The response time was set to 0.5 s and the bandwidth
was set to 1 nm. The ﬁnal spectrum represents the accumulated aver-
age of 10 consecutive scans. The raw data was converted to mean res-
idue ellipticity (MRE) according to [43] using the formula:
MRE ¼ θ 0:1MRWð Þ=cl
where θ is the measured ellipticity in mdeg, c is the concentration in
mg/ml, l is the cuvette pathlength in cm and MRW is the mean resi-
due weight of the peptide. MRW is deﬁned as:
MRW ¼ MW= n−1ð Þ
where MW is the molecular weight of the peptide in daltons and n is
the number of residues in the peptide.
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Approximately 1 mg of peptide was dissolved in 500 μl of a 4:4:1
co-solvent mixture of CDCl3: methanol-d3: H2O. The sample was
transferred to an NMR tube and immediately ﬂame sealed to prevent
evaporation of the organic solvents. This co-solvent has been used
previously as a membrane mimetic to examine the solution struc-
tures of other antimicrobial peptides [15, 44].
Two dimensional NOESY, TOCSY and COSY spectra were collected at
298°K on a Bruker Avance 600 MHz spectrometer for all of the peptide
samples. To improve spectral resolution for the LFchimera sample, spec-
tra were also acquired on a Bruker Avance 700 MHz spectrometer. Mix-
ing times used in the NOESY experiments were 0.25 s on the 600 MHz
and0.5 s on the 700 MHz spectrometer. For the TOCSY experiments,mix-
ing times of 0.1 and 0.12 swere used for the 600 MHz and 700 MHz spec-
trometers respectively. Spectra acquired on the 600 MHz spectrometer
were collected with 4096×512 data points in the F2 and F1 dimensions
respectively, while the spectra from the 700 MHz spectrometer had
4096×600 data points in these two dimensions. The spectral widths for
the spectra from the 600 MHz and 700MHz spectrometers were
8503.401 Hz and 8992.806 Hz respectively. Water suppression was
achieved using excitation sculpting [45].
All spectra were processed using the NMRPipe software package
[46]. The 2-D data were zero ﬁlled once in each dimension and Fouri-
er transformed with a shifted sine-bell function. Spectral analysis was
performed in NMRView version 5.2.2.01 [47] and chemical shifts
were assigned according to well established methods [48].
Starting structures for the simulated annealing calculations were
generated with CNS [49]. To generate the initial template structure
of LFchimera, the topology ﬁles produced by CNS were manipulated
to artiﬁcially insert the covalent amide link between the carbonyl C
atom of Gly30 and the ζN atom of Lys280. Broad dihedral restraints
were imposed on all of the non-Gly residues to keep the initial phi
and psi angles within allowable regions of the Ramachandran plot.
Peptide structures were calculated with ARIA 1.2 [50] using NOE re-
straints derived from the 2D 1H-NOESY spectrum. Nine iterations of
the simulated annealing protocol were performed with 20 structures
generated in the ﬁrst 7 iterations followed by 40 and 100 in the ﬁnal
two iterations. The 20 lowest energy structures from the ﬁnal itera-
tion were analyzed with Procheck [51] and visualized with MOLMOL
[52].3. Results
3.1. Differential scanning calorimetry
The inﬂuence of LFcin17–30, LFampB and LFchimera on the phase
transitions of DPPG lipid suspensions is shown in Fig. 2. Pure DPPG
lipids have a main phase transition peak at ~40 °C corresponding to
the melting temperature (Tm) of the lipids converting from the gel
phase to the liquid crystalline phase. In addition, a pretransition
peak, corresponding to a conversion from the lamellar gel phase to
the rippled gel phase, occurs at ~30 °C. At the lowest peptide:lipid
ratio of 1:100, LFcin17–30 and LFampB had relatively mild effects
on the phase transitions of the DPPG lipids. The Tm of the main
phase transition and the pretransition is largely unaffected, as is the
shape of these peaks. The LFchimera causes a broadening of the pre-
transition peak at this concentration, suggesting that this peptide in-
teracts at the bilayer surface, however the main phase transition is
also largely unaffected. As the concentration of peptide increases to
a ratio of 1:10, all of the peptides cause substantial changes in the
heating scans. LFcin17–30 has a sharp transition at ~40 °C as well as
a broad transition centered at 43 °C. The higher temperature peak
could be due to LFcin17–30 binding to the DPPG lipids, which rigid-
iﬁes the bilayer and impedes the conversion to the liquid crystallinephase, while the lower temperature peak corresponds to DPPG lipids
with no bound peptide. The effect of LFampB at high concentrations is
opposite to LFcin17–30 with a broad transition appearing below the
main phase transition and a sharp transition occurring at 38.9 °C.
This suggests that LFampB destabilizes the gel phase and promotes
the formation of the liquid crystalline phase. When the peptides
were tested in combination with each other at the 1:10 ratio, the
sharp main phase transition of unbound DPPG disappears and broad
transitions at 38.7 °C and 43.7 °C emerge in the thermogram, consis-
tent with the DPPG lipids interacting with LFcin17–30 and LFampB
individually (Supplementary Figure S1).
The thermogram of LFchimera at a peptide:lipid ratio of 1:10 is
unlike those described above and there appears to be a unique inﬂu-
ence of the heterodimer on the phase behaviour of DPPG lipids. The
main phase transition is broadened slightly with a sharp transition
centred at a temperature of 40.3 °C, suggesting that the LFchimera
impedes the formation of the liquid crystalline phase, similar to
LFcin17–30. However, there is a low temperature shoulder to this
main transition peak, which is similar to the broad shoulder seen in
the thermogram of LFampB mixed with DPPG. Based on these obser-
vations, it is apparent that LFchimera has a strong effect on the phase
transitions of DPPG lipids and that this effect is different from the
constituent peptides or a mixture of the two.
3.2. Calcein leakage
LFcin17–30, LFampB or a mixture of the two peptides did not in-
duce signiﬁcant calcein leakage from either LUVs made from E. coli
PLE or a 3:1 ratio of ePE:ePG (Fig. 3A and B). The lipid composition
of E. coli PLE is 67% PE, 23% PG and 10% negatively charged cardiolipin
(Avanti Polar Lipids Inc., avantipolarlipids.com), which is comparable
to the negative charge present in the 3:1 ePE:ePG LUVs. Slightly
higher leakage occurred when the peptides were added to LUVs com-
posed of 1:1 ePE:ePG phospholipids (Fig. 3C). These LUVs have a
greater net negative charge, due to the higher PG content, suggesting
that electrostatic attractions with the cationic peptide contribute to
the membrane disrupting ability of these two peptides. The addition
of LFchimera to the LUVs resulted in signiﬁcantly higher calcein re-
lease from all the negatively charged liposomes. For LUVs composed
of E. coli PLE and 3:1 ePE:ePG, LFchimera induced 25% and 40% respec-
tively at the highest peptide to lipid ratio. The membrane perturbing
properties of LFchimera were also enhanced by increasing the nega-
tive charge on the LUV surface. Nearly 90% leakage was observed
when LFchimera was added to vesicles composed of 1:1 ePE:ePG at
a peptide:lipid ratio of 1:10. These results demonstrate that the LFchi-
mera has enhanced membrane destabilizing activity compared to the
constituent peptides.
3.3. Liposome fusion
Membrane fusion was examined by incubating ePE:ePG liposomes
with increasing amounts of peptide and monitoring the change in ab-
sorbance of the solution at 400 nm [38,42]. The results from the lipo-
some fusion assay are shown in Fig. 4. LFampB did not cause any
vesicle fusion of negatively charged liposomes, while the addition of
LFcin17–30 resulted in substantial increases in the absorbance values.
The effect of adding LFchimera to the liposome suspensions was even
more pronounced with a signiﬁcant increase in absorbance at the low-
est peptide:lipid ratio of 1:100 and absorbance values that were consis-
tently higher than those observed for LFcin17–30 at equivalent peptide
concentrations. The equimolar mixture of LFampB and LFcin17–30
caused liposome fusion that was practically identical to that seen for
LFcin17–30 on its own (data not shown) suggesting that membrane fu-
sion is a property of the LFcin peptide alone. These results demonstrate
that LFcin17–30 induces fusion of negatively charged liposomes and
that this fusion capacity is enhanced in the LFchimera peptide.
Fig. 2. DSC heating scans of pure DPPG compared to lipid suspensions containing LFcin17–30, LFampB and LFchimera at peptide to lipid molar ratios of 1:100, 1:50 and 1:10. The
insets in each panel show the pretransition peak seen in the pure DPPG lipid sample. In addition, the main phase transition regions for each peptide sample at a ratio of 1:10 have
been expanded to emphasize the features of the thermogram. All experiments were carried out at a lipid concentration of 1 mg/ml.
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Structural analysis by CD spectroscopy provides a qualitative pic-
ture of the structural elements that are present in a given peptide so-
lution. The ellipticity values measured by the spectropolarimeter are
directly related to the number of amide bonds absorbing the circular-
ly polarized light in the wavelength range. As expected, LFcin17–30 is
the smallest peptide and has the smallest ellipticity intensity, while
LFchimera is the largest molecule and has the greatest θobs. It should
be noted that the spectrum collected for a sample containing 50 μM
each of LFcin17–30 and LFampB was essentially identical to the
curve obtained when the spectra of the individual peptides were
added together (Supplementary Fig. S2). This is true for both the buff-
er and SDS samples and it suggests that the individual peptides do not
physically interact with each other in solution and fold independently
in the presence of detergent micelles.Converting the ellipticity values to mean residue ellipticity cor-
rects for the different molecular weights of the peptides and provides
information about the secondary structure of the peptide. All peptides
are largely unstructured in aqueous solution as indicated by the pres-
ence of a strong minimum peak at 200 nm (Fig. 5A). The intensity of
the LFchimera peak at ~200 nm is larger than the other peptides pos-
sibly due to some structural conformation imposed on the hybrid
peptide by the unique lysine linkage. In the presence of SDS micelles,
negative peaks at 208 and 222 nm emerge in all the spectra, charac-
teristic of peptides adopting helical conformations (Fig. 5B). For
LFcin17–30, the intensities of the peaks at 208 and 222 nm are fairly
weak. In fact, there is still a signiﬁcant peak at ~205 nm, likely arising
from peptide regions that remain unstructured in the presence of mi-
celles. For LFampB and LFchimera, stronger minima are seen at 208
and 222 nm and the resulting spectra overlap almost identically
with each other. This suggests that these two molecules have similar
Fig. 3. Calcein leakage induced by LFampB (diamonds), LFcin17–30 (triangles), a mix-
ture of the two peptides (circles), and LFchimera (ﬁlled boxes). The percentage of cal-
cein dye released from LUVs composed of E. coli PLE (A), 3:1 ratio of ePE:ePG (B) and a
1:1 ratio of ePE:ePG (C) were measured. The error bars represent the standard devia-
tion of three separate trials.
Fig. 4. Fusion of ePE:ePG liposomes induced by LFcin17–30 (triangles), LFampB (dia-
monds) and LFchimera (squares). An increase in the absorbance at 400 nm is indicative
of liposome fusion. The error bars represent the standard deviation of three separate
trials.
Fig. 5. Far UV CD spectra of LFampB (green), LFcin17–30 (blue), an equimolar mixture
of the two peptides (red) and LFchimera (black). Data are shown in units of mean res-
idue ellipticity (MRE). Spectra were acquired in buffer (A) and in the presence of
200 mM SDS (B). All spectra were recorded at room temperature at individual peptide
concentrations of 50 μM.
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assigned to speciﬁc residues. The spectrum of LFampB mixed with
LFcin17–30 represents an average of the secondary structure that is
present and it is evident that the LFchimera possesses more helical
conformation when bound to micelles than the mixture of the two
peptides. Unfortunately, using only these results, it is unclear if the in-
creased helical content of LFchimera is from the LFcin17–30 portion
adopting a helical conformation or an extension of the N-terminal
helix in LFampB, or a combination of both. Regardless, it is evident
from the CD results that the linking lysine residue inﬂuences the mi-
celle bound structure of the LFchimera peptide.3.5. NMR results
Initially, we sought to determine the solution structure of the
LFchimera bound to SDS micelles since this detergent is commonly
used as a bacterial membrane mimic in NMR studies of antimicrobial
peptides. In addition, the NMR solution structures of SDS bound
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our group, which would allow for structural comparison among the
peptides. Unfortunately, the 2D 1H-NOESY spectrum of the LFchimera
in the presence of SDS micelles had poor peak dispersion and the in-
dividual peaks could not be resolved (Supplementary Fig. S3). In an
effort to improve the quality of the NMR spectra, a 4:4:1 mixture of
chloroform, methanol and water was used as an alternative mem-
brane mimetic. The resulting spectra were of much better quality
with very well deﬁned peaks and excellent peak dispersion making
subsequent structure calculations possible (Supplementary Fig. S3).
NMR samples of LFcin17–30 and LFampB in the same co-solvent
mixture were prepared to facilitate structural comparisons to LFchi-
mera. Good peak dispersion was also observed for these two peptides
allowing for complete chemical shift assignment of all protons (Fig. 6).
It should be noted that the solution structure determination of
LFampB was complicated by a large number of αH peaks between
4.1 and 4.3 ppm, resulting in signiﬁcant peak overlap in this region.
A similar phenomenon was seen in the spectrum of LFcin17–30Fig. 6. NH–αH region of the 2D 1H-NOESY spectra of LFampB (A) and LFcin17–30 (B) in
a co-solvent mixture of chloroform, methanol and water collected on a 600 MHz spec-
trometer. All the chemical shifts for each peptide were assigned and the sequential
connectivity between NH (i) and αH (i−1) peaks are indicated. Note the cluster of
peaks that occurs between 4.1 and 4.3 ppm in the LFampB spectrum and the clustering
of peaks between 7.9 and 8.2 ppm in the LFcin17–30 spectrum.where several backbone amide chemical shifts appeared between
7.9 and 8.2 ppm, making unambiguous assignment of intermolecular
NOEs in this region extremely difﬁcult.
The solution structure of LFampB in the co-solvent mixture is
shown in Fig. 6. A well deﬁned N-terminal helix emerges in LFampB,
while the cationic C-terminal region remains relatively unstructured.
The backbone RMSD across the entire peptide is 1.552 Å but this
drops to 0.919 Å across residues 265–278 (Fig. 7A). At ﬁrst glance
this appears to be a fairly large RMSD but this can be attributed to a
lack of unambiguous NOEs between residues 272–277. The complica-
tion of the overlapping peaks between 4.1 and 4.3 ppm (described
above) is compounded by the fact that all of the αH resonances be-
tween residues 272 and 277, inclusively, are found in this region of
the spectrum. As a result, key medium range NOEs (dNN(i,i+2),
dαN(i,i+2), dαN(i,i+3) and dαN(i,i+4)), that are important for
deﬁning helical structures, could not be unambiguously assigned for
use in the structure calculations. If the backbone atoms of LFampB
are ﬁt across residues 265–272, whose medium-range NOEs were
readily assigned, an extremely well deﬁned helical conformation
emerges with a backbone RMSD of 0.305 Å.
The side chain orientations of LFampB in the co-solvent are com-
parable to those seen in the SDS bound form of the peptide. The N-
terminal helix is largely amphipathic with the hydrophobic residues
appearing in a hydrophobic patch bordered by the aromatic side
chains of Trp 268 and Phe 278 (Fig. 8). A number of charged residues
appear on the opposite face of this hydrophobic patch, including
three positively charged Lys residues at positions 269, 273 and 277
as well as a negative charge from Glu 276. The remaining cationicFig. 7. Solution structure of LFampB in the co-solvent mixture. A relatively well deﬁned
N-terminal helix emerges when the backbones of the 20 lowest energy structures are
superimposed across residues 265–278 (A). The ribbon diagram of a representative
structure of LFampB shows the N-terminal helix and the orientation of the side chains
in the peptide. Side chains are coloured as follows: hydrophobic — green, positively
charged — blue, negatively charged — red and uncharged — magenta (B). The surface
charge distribution of the peptide shows the amphipathic nature of the N-terminal
helix (C). The panel on the left shows the peptide with the hydrophobic surface facing
the reader and the panel on the right shows the charged surface on the opposite face of
the structure.
Fig. 8. Solution structure of LFcin17–30 in a 4:4:1 mixture of chloroform, methanol and
water. The peptide adopts a short helical conformation between residues 20–28, with a
backbone RMSD of 0.503 Å (A). The ribbon diagram of a representative structure of
LFcin17–30 clearly shows this short helical segment. The side chain orientations are
also shown and have been colored using the same scheme described in Fig. 6. In addi-
tion, the cysteine residue is shown in yellow (B). The surface charge distribution of the
peptide does not show a distinct amphipathic structure (C). The panel on the left
shows the peptide in the same orientation as in B and the panel on the right shows
the opposite face.
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pared to the rest of the peptide.
The structure of LFcin17–30 in the co-solvent mixture is also not
very well deﬁned across the length of the peptide, as indicated by a
large backbone RMSD of 1.327 Å across all residues. However, if the
backbone atoms of the 20 lowest energy structures are overlaid be-
tween Arg 20 and Lys 28, the RMSD drops to 0.503 Å, corresponding
to a small helix-like conformation (Fig. 9). Contrary to the LFampB
structure, the solution structure of LFcin17–30 in the co-solvent is
not very amphipathic. The two Trp residues at positions 22 and 24 ap-
pear on the same face of the peptide, forming a small hydrophobic
region, but the cationic Lys and Arg residues are fairly evenly distrib-
uted across the surface of the molecule.
The structure of the LFchimera in the membrane mimetic solvent
is interesting because it is the ﬁrst high resolution structure reported
for a molecule containing this unique lysine linkage. The lysine link-
age between LFcin17–30 and LFampB keeps the C-termini of these
two peptides in close proximity to each other as would be observed
if they were excised directly from the crystal structure of bovine lac-
toferrin [18]. The solution structure of the LFchimera presented here
indicates that the linker does not maintain the orientation of
LFcin17–30 relative to LFampB compared to these stretches in intact
lactoferrin. However, the lysine linker does induce structural changes
in the LFampB and LFcin17–30 portions of LFchimera compared to the
conformations of the individual peptides on their own.The NOESY spectrum of LFchimera collected on the 700 MHz spec-
trometer yielded sharper peaks and better dispersion compared to
the spectra collected at a lower magnetic ﬁeld strength. This alleviat-
ed some of the peak overlap that was seen in the LFampB and
LFcin17–30 spectra, which would have made solving the structure
of such a large antimicrobial peptide using only proton NMR tech-
niques virtually impossible. All of the chemical shifts of the protons
in the LFchimera peptide were assigned based on the NOESY spec-
trum and the backbone connectivity was easily determined. In addi-
tion, the presence of the peptide bond between the C-terminus of
LFampB and the amide on the side chain of the linking lysine residue
was conﬁrmed through the identiﬁcation of cross peaks in the NOESY
spectrum (Fig. 9).
Initial analysis of the LFchimera structure revealed a backbone
RMSD of 4.278 Å when the 20 lowest energy structures were ﬁt
across all residues. This could suggest that this peptide does not
adopt a well deﬁned overall conformation in the co-solvent mixture.
There are only a handful of NOEs between the LFampB and
LFcin17–30 portions of LFchimera and most of these are limited to in-
teractions between the side chain of Arg 284 and the side chain pro-
tons of the Lys linker. No NOEs were observed between the two
peptides further away from the connecting lysine residue resulting
in a large degree of relative conformational freedom between the
two polypeptide chains. However, a closer inspection of the LFchi-
mera structure in the co-solvent mixture reveals that the LFampB
and LFcin17–30 portions of LFchimera fold independently from each
other under these conditions.
Analysis of the LFampB and LFcin17–30 portions of LFchimera re-
veals well deﬁned backbone conformations for each constituent poly-
peptide in the heterodimer. The backbone RMSD of all the LFampB
residues in LFchimera is 0.933 Å (Fig. 10A, right) which corresponds
to a fairly well deﬁned helical conformation that extends into the nor-
mally ﬂexible cationic C-terminal region of LFampB (see Fig. 7). The
backbone RMSD of all the LFcin17–30 residues in LFchimera is
2.212 Å but the structure converges to a well deﬁned conformation
between Arg 20 and Gly30 as seen by a comparatively low backbone
RMSD of 0.746 Å across these eleven residues (Fig. 10A, left). This is a
comparable RMSD to that calculated for a similar region of free
LFcin17–30 (see above) but it includes two extra residues indicating
that, in the co-solvent, this portion of the LFcin17–30 peptide is
more ordered in the LFchimera heterodimer.
Knowing the structure of LFampB, LFcin17–30 and LFchimera in
the co-solvent solution provides an opportunity to compare between
the structures and examine the structural differences induced by the
presence of the linking lysine residue. If we compare the TOCSY spec-
tra of the three molecules, a number of the peaks from LFcin17–30
and LFampB overlap with the peaks of the LFchimera (Supplementary
Fig. S4A). The peaks that are shifted represent residues that have a
different conformation in the LFchimera structure. As expected, the
peaks that are signiﬁcantly shifted in the LFchimera TOCSY spectrum
correspond to residues that are close to the linking lysine residue
(Supplementary Fig. S4B). This underscores the structural impact of
the Lys linker on the conformation of the hybrid peptide.
A representative structure of the LFchimera in the co-solvent is
shown in Fig. 10B. The LFampB portion forms a nearly contiguous
helix across the length of the peptide, including a number of residues
in the cationic C-terminal region. The increased helical content in
LFcin17–30 is even more pronounced with a fairly well deﬁned heli-
cal conformation observed between Arg20 and Gly30. Overall, this
represents an ordering of the C-terminal regions of both peptides
when they are joined together in the LFchimera heterodimer.
The secondary structure of LFchimera in the miscible co-solvent
supports the CD results, which indicated that the hybrid peptide
adopted a mainly α-helical conformation when bound to SDS mi-
celles. Based on what is known about the solution structure of
LFampB, there are a number of residues in the C-terminal region
Fig. 9. Sequence speciﬁc assignment for the LFchimera based on 2D 1H-NOESY spectrum collected on a 700 MHz spectrometer. The sequence of LFchimera is also shown and has
been highlighted according to the labelled peaks in the NOESY spectrum. NOE cross peaks to the linking lysine residue are also indicated.
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structure reveals a number of residues that also do not form helices,
but these are found mostly in the N-terminal region of the
LFcin17–30 portion. This explains why the CD spectra of LFampB
and LFchimera overlap with each other (Fig. 3B) since both polypep-
tides contain helical regions with a small fraction of residues adopting
random coil conformations.
A survey of the surface charge distribution in LFchimera indicates
that the peptide does not adopt an amphipathic structure over the en-
tire surface of the peptide. The amphipathic helix in LFampB persists
in the LFchimera structure, while the LFcin17–30 region still does not
show a clear separation of charged and hydrophobic residues
(Fig. 10C).
Structural statistics for the solution structures of LFampB,
LFcin17–30 and LFchimera in the co-solvent mixture are shown in
Table 1. It should be noted that the residues that occupy the disal-
lowed regions of the Ramachandran plot in LFchimera are found in
the ﬂexible N-terminal region of the LFcin17–30 polypeptide. There-
fore, these disallowed dihedral angles can be attributed to a large de-
gree of conformational ﬂexibility in the peptide as opposed to a
signiﬁcant structural feature of the peptide backbone.
4. Discussion
Antimicrobial peptides are seldom found in isolation in nature.
Many peptides are biosynthetically produced in combination with a
variety of others, yielding a potent cocktail of antibiotic molecules ca-
pable of challenging a range of pathogenic micro-organisms that
threaten the host. Many animals employ mixtures of antimicrobial
peptides as important components of their innate immune systems.
For instance, amphibians secrete a number of antimicrobial peptides
and frog skin has proven to be a wealthy source of potent antimicro-
bial sequences [53–59]. In insects, antimicrobial peptides make up a
signiﬁcant portion of their innate immune response [60, 61]. Cows
generate at least 38 antimicrobial peptides which differ signiﬁcantlyin their sequences and respective structures [62]. Even humans pro-
duce an array of antimicrobial peptides including ubiquicidin, LL-37,
HBD1–3 and HNP1, among others [63].
Since antimicrobial peptides often act in combination, joining dif-
ferent sequences may be an effective strategy to develop novel antibi-
otics with enhanced antimicrobial potency. Numerous studies have
examined the antimicrobial activity of peptide sequences joined to-
gether in one continuous polypeptide chain. For example, several
studies have focused on hybrid peptides which combine portions of
Cecropin A and melittin [64–68]. A similar strategy has been used to
generate a series of hybrid peptides between Cecropin B and thanatin,
one of which exhibited moderate antifungal activity not seen in either
of the parent peptides [69].
Some antimicrobial peptides exist in dimeric form when bound to
vesicles, such as magainin 2 [70] and its derivative, MSI-78 [71]. This
observation has led to the generation of covalently linked peptide di-
mers, typically through the incorporation of cysteine residues into the
peptide sequences followed by oxidation to generate a disulphide
linked dimer. This strategy has been successfully used to generate
parallel and antiparallel dimers of magainin 2 [72] and dimeric
forms of lentivirus-derived antimicrobial peptides [73]. In both
cases, peptide dimerization resulted in hybrid peptides with en-
hanced antimicrobial activity.
The lysine linkage used in the LFchimera molecule has also been
used to join antimicrobial peptides together; however, the effective-
ness of Lys dimerization on the biological properties of peptides is
unpredictable. For instance, a lysine branched dimer of a de novo dec-
apeptide was found to have potent activity against E. coli and S. aureus
while being relatively non-cytotoxic and resistant to proteases [74].
In contrast, the dimerzation of a tritrpticin derived peptide, PST13-
RK, through both Cys- and Lys-linkages yielded a dimeric peptide
with modestly higher antibacterial activity accompanied by an unde-
sired increase in toxicity towards mammalian cells [75].
One of the best examined examples of a linked heterodimer of two
antimicrobial peptides is that between two frog peptides, magainin2
Fig. 10. Overlay of all the backbone atoms of the 20 lowest energy structures of LFchi-
mera in the co-solvent mixture of chloroform:methanol:water (A). The superposition
of the backbone atoms corresponding to the residues of LFampB reveals a well deﬁned
helical conformation with a backbone RMSD of 0.933 Å (A, right). When the backbone
atoms are overlaid across residues 20–30 of LFcin17–30, the RMSD is 0.746 Å (A, left).
The ribbon diagram of a representative structure of the LFchimera in the co-solvent
mixture shows signiﬁcant helical conformation (B). Residues have been coloured
using the same scheme seen in previous ﬁgures. The linking lysine residue connecting
LFampB and LFcin17–30 is shown in grey. The surface charge distribution of LFchimera
reveals no overall amphipathicity in the heterodimer (C). The LFchimera molecule is
shown in the same orientation as in B and rotated along the X-axis to show the oppo-
site face. Cationic surfaces are coloured in blue, anionic regions are shown in red and
uncharged portions are white.
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the African clawed frog, Xenopus laevis [59, 76], and individually they
posses broad spectrum antimicrobial activity against a variety of bac-
terial species. When tested in combination, magainin 2 and PGLa
demonstrated marked synergism, both in their antimicrobial activi-
ties and in their membrane destabilizing properties [77, 78]. This ob-
servation led to the synthesis of a hybrid peptide where both peptides
were linked together through a disulphide bond [6]. This hybrid pep-
tide displayed similar activity compared to the mixture of the two
peptides and the solution structure of this hybrid peptide bound to
DPC micelles demonstrated that the two helices are partially held to-
gether by a series of interstrand NOEs between magainin 2 and PGLa
[7].
Many of the studies on dimerized antimicrobial peptides, through
either Cys- or Lys-linkages, have limited their structural analysis toCD spectroscopy to look at the overall conformational changes that
occur upon lipid binding. The NMR structure of LFchimera presented
here represents the ﬁrst high-resolution structure of a peptide con-
taining this unique Lys-linkage and it is a signiﬁcant contribution to-
wards furthering our understanding of the mode of action of this class
of linked antimicrobial peptides. Structural characterization of
LFampB, LFcin17–30 and LFchimera has previously been performed
using CD spectroscopy [33]. All of the peptides were unstructured in
aqueous buffer, consistent with the CD results presented here, but
when mixed with DMPG liposomes; each of the peptides underwent
a conformational change. In agreement with our results, LFcin17–30
changed conformation but it did not form a strong α-helix, while
LFampB mixed with the anionic liposomes yielded CD spectra charac-
teristic of α-helical structure. The CD spectrum of LFchimera mixed
with DMPG also appeared to be largely helical, but the intensity of
the peaks at 208 and 222 nm were largely reduced compared to
LFampB. This could be due to aggregation of the peptide with the
DMPG liposomes, as seen in the fusion assay with ePE:ePG liposomes
(Fig. 4), which would result in a loss of CD signal. Full length bovine
LFcin has the ability to induce fusion of negatively charged liposomes
[38] and it is evident that this is a trait that is retained in LFcin17–30
and LFchimera. Regardless, the increased helical content in the LFchi-
mera upon membrane binding seen in the CD results is likely an im-
portant structural feature afforded to this molecule by the linking
lysine residue.
A brief discussion regarding the choice of the NMR solvent used in
this study is warranted owing to the inherent differences between
aqueous samples containing detergent micelles and co-solvent mix-
tures containing organic solvents. Typically, NMR structural studies
of antimicrobial peptides are carried out in the presence of deuterated
detergent micelles [79]. Unfortunately, the spectrum of an NMR sam-
ple containing the LFchimera and SDS was of such poor quality that
further structural characterization was not possible. The poor spectral
resolution might be explained if we assume that the LFampB and
LFcin17–30 regions of LFchimera bind to separate SDS micelles. Bind-
ing of each peptide region to individual micelles would lead to larger
LFchimera/micelle aggregates that tumble slowly in solution and
could explain the broad peptide signals seen in the NOESY spectrum
(Supplementary Fig. S3). Indeed, we did observe evidence for mem-
brane fusion in our liposome aggregation studies.
The co-solvent mixture of 4:4:1 chloroform, methanol and water
is considered to be a reasonable mimic of the membrane environ-
ment. Many functional properties of membrane associated proteins
are conserved when they are dissolved in this single phase mixture
[80, 81]. Additionally, a variety of NMR structural studies of trans-
membrane proteins have been published using this co-solvent mix-
ture [80, 82, 83] and our group has used this mixture to examine
the solution structures of membrane associated antimicrobial pep-
tides [15, 44].
The most compelling evidence that the co-solvent mixture yields
an accurate representation of the solution structure of an antimicrobi-
al peptide bound to a membrane involves comparing the SDS bound
structures of LFcin17–30 and LFampB to the structures determined
in the co-solvent mixture. The structure of LFampB in the co-solvent
mixture is remarkably similar to the SDS bound conformation of the
peptide [31]. The characteristic ﬂexibility seen in the C-terminal re-
gion and the amphipathic N-terminal helix is present in both struc-
tures. There may be a slight increase in the helical content of the
co-solvent derived structure but this can be attributed to the promo-
tion of helical conformation in peptides by organic solvents, as is the
case with 2,2,2-triﬂuoroethanol [84, 85].
The NMR solution structure of LFcin17–31 bound to SDS micelles
has previously been reported [23] and compared to our LFcin se-
quence, this peptide has an additional Ala residue at the C-terminus
and the C-terminal carboxyl group is amidated. The SDS bound
LFcin17–31 peptide does not adopt a helical conformation and
Table 1
Structural statistics for the ARIA generated structures of LFampB, LFcin17–30 and LFchimera in a co-solvent mixture of choloroform, methanol and water.
LFampB LFcin17–30 LFchimera
No. of distance restraints
Unambiguous NOEs 272 208 605
Ambiguous NOEs 15 13 41
Unassigned NOEs 0 0 0
Total NOEs 287 221 646
Dihedral restraints 18 12 31
Geometry analysis — root mean square
Bonds (Å) 1.48×10−3+/−4.0×10−5 8.17×10−4+/−1.2×10−4 2.09×10−3+/−5.0×10−5
Angles (degree) 0.302+/−1.8×10−3 0.284+/−2.6×10−3 0.343+/−5.8×10−3
Impropers (degree) 0.117+/−6.7×10−3 0.103+/−8.7×10−3 0.163+/−1.6×10−2
Dihedrals (degree) 37.81+/−0.37 37.44+/−0.78 9.18+/−0.37
van der Waals (kcal/mol) 5.76+/−0.27 3.29+/−0.15 46.75+/−1.99
Ramachandran space (%)a
Most favoured 78.8 56.7 66.7
Additionally allowed 21.2 43.4 29.1
Generously allowed 0.0 0.0 2.9
Disallowed 0.0 0.0 1.2
a Calculated by Procheck [51].
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structure of LFcin17–31 is moderately amphipathic in contrast to
the structure of LFcin17–30 determined in the co-solvent mixture. It
seems that the co-solvent mixture induces slightly more helical con-
formation in the LFcin17–30 backbone, which alters the orientation
of the Arg and Lys residues on the surface of the peptide and makes
it difﬁcult to identify a continuous hydrophobic face. However, the
two Trp residues at positions 22 and 24 do appear on the same side
of the LFcin17–30 structure. This small hydrophobic face formed by
these two Trp residues is similar to a portion of the hydrophobic sur-
face seen in the SDS bound LFcin17–31 peptide. Trp residues are
known to have a preference for the interfacial region of a bilayer
[86, 87] and recent molecular dynamics simulations of bovine LFcin
performed in 4:4:1 chloroform–methanol–water suggests that these
two Trp residues anchor the peptide to the surface of the bacterial
membrane [88]. This offers further support that the LFcin17–30 struc-
ture determined in this study is representative of the peptide confor-
mation bound to a bilayer.
Based on these observations, we can conclude that the solution
structure of LFchimera is a reasonable representation of the structure
of the peptide bound to a bacterial membrane. However, contrary to
the solution structure of the magainin2-PGLa heterodimer discussed
earlier [7], interstrand NOEs between the LFampB and LFcin17–30
portions of LFchimera were not observed in the 2D NOESY spectrum.
This suggests that the increased antimicrobial activity of the LFchi-
mera is not related to a combined structural component involving
both peptides. Instead, it is likely related to a combination of the
mechanisms of action of LFcin17–30 and LFampB, which are en-
hanced in the LFchimera peptide.
The membrane destabilizing activity seen in the calcein leakage
results is difﬁcult to ascribe to either the LFampB or the LFcin17–30
region of the LFchimera. Both peptides had signiﬁcant effects on the
thermotropic phase behaviour of DPPG lipid suspensions but neither
peptide caused signiﬁcant leakage from calcein encapsulated LUVs.
Full length bovine LFcin has been shown to induce leakage from neg-
atively charged liposomes [38], but the extent of membrane disrup-
tion appears to depend on the nature of the acyl chain [89].
Conversely, calcein leakage experiments conducted with bovine
LFcin fragments have demonstrated that they cause poor leakage
from all types of vesicles, regardless of acyl chain composition [19,
23]. For lactoferrampin, this is the ﬁrst time that calcein leakage has
been reported for this peptide, but it is known that LFampB preferen-
tially interacts with anionic phospholipids [30, 31] and recent evi-
dence suggests that this peptide can induce a micellar cubic phase
in DMPC/DMPG liposomes [90]. Previously published DSC results for
LFcin17–30 and LFampB mixed with DMPG liposomes revealed thatthese peptides inﬂuenced lipid organization at relatively high peptide
concentrations, while the LFchimera caused more dramatic changes
to the phase transition of DMPG liposomes at lower peptide concen-
trations [33]. This is in agreement with the DSC results presented
here wherein the pretransition peak of DPPG is signiﬁcantly affected
in the LFchimera sample at a lipid:peptide ratio of 1:100 while the
pretransition peak is largely intact in the presence of LFcin17–30 or
LFampB at the same concentration. A number of studies have exam-
ined the effects of these peptides on intact bacterial cells. Atomic
force microscopy of E. coli and S. aureus treated with bovine LFcin
revealed that the peptide had signiﬁcant effects on the bacterial
membrane structure without disrupting the overall membrane integ-
rity [20]. Freeze-fracture transmission electron microscopy studies of
LFampB and LFcin17–30 demonstrated that both peptides have dra-
matic effects on the plasma membrane integrity of C. albicans and E.
coli [29] and severe membrane damage was observed when LFchi-
mera was added to V. parahaemolyticus [34]. Evidently, the LFchimera
heterodimer signiﬁcantly destabilizes lipid bilayers, which likely ex-
plains some of the increased activity of the hybrid peptide.
The increase in membrane permeability induced by the LFchimera
is correlated with an increased positive charge of the LFchimera com-
pared to the individual peptides. The net positive charges of LFampB
and LFcin17–30 are +4 and +6 respectively. When combined in
the LFchimera peptide, the net charge becomes +12 (the LFampB
carboxyl group is in a peptide bond with the ε-amino group on the
Lys linker and the α-carboxyl group on the Lys linker is amidated, ef-
fectively removing two negative charges) which should result in a
stronger electrostatic attraction to the negatively charged surface of
bacterial cells. This is consistent with the increased leakage observed
from LUVs with higher negative charge on their surface, as the elec-
trostatic attraction is stronger towards the highly cationic LFchimera
molecule. How this increased cationic nature of LFchimera leads to in-
creased membrane permeability is still unclear but we can speculate
based on the mechanism of action proposed for LFampB. Binding of
LFampB to the microbial surface involves an initial electrostatic at-
traction between the cationic residues in the C-terminal region of
the peptide followed by folding and insertion of the N-terminal am-
phipathic helix into the interfacial region of the phospholipid bilayer
[30–32]. This electrostatic attraction is a critical interaction for the
mode of action of LFampB, since adding positive charges to the C-
terminal region of human lactoferrampin has been shown to increase
the antimicrobial activity of this peptide [32]. The addition of
LFcin17–30 to the C-terminus of LFampB adds six cationic residues
to the normally ﬂexible C-terminal portion of LFampB. This increased
positive charge in LFchimera might drive the hybrid peptide to the
bacterial membrane which promotes the formation of the N-
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creases the membrane perturbing activity of the peptide. An exten-
sion of the increased positive charge when LFcin17–30 and LFampB
are joined together is that this also increases the hydrophobic bulk
in the heterodimer, which would presumably favour interactions be-
tween the peptide and the hydrophobic core of a membrane.
Determining the solution structure of micelle bound antimicrobial
peptides continues to be of interest to researchers in the ﬁeld as evi-
denced by recent high resolution NMR structures reported for micelle
bound LL-37 [91], lactophoricin [92], and papiliocin [93]. However,
the limitations of using micellar and membrane mimetics in NMR
spectroscopy are well known. There is signiﬁcant positive curvature
at the surface of a micelle which can inﬂuence the structure of a pep-
tide. Miscible co-solvents alleviate the curvature problem and can
help improve spectral resolution. However, interactions between
the peptide and lipid head groups or acyl chains cannot be deter-
mined using this method. Therefore, based on the NMR structure of
the LFchimera in the co-solvent mixture, we can only speculate as
to how this hybrid peptide disrupts phospholipid bilayers at the mo-
lecular level. Future studies could involve the use of bicelles [94] or
solid state NMR with lipid and peptide mixtures [95], both of which
could provide signiﬁcant insights into the conformation and orienta-
tion of the peptide in a bilayer. Furthermore, molecular dynamics
studies [96] could be used to examine the conformation of LFchimera
as it interacts with membranes.
Finally, in addition to causing membrane perturbations, it is possi-
ble that LFchimera has an intracellular target for antimicrobial activi-
ty. In an attempt to explain the apparent weak membrane activity of
bovine LFcin, it has been suggested that this peptide crosses the bac-
terial membrane and binds to intracellular targets [19, 23, 97]. In-
deed, bovine LFcin localizes to the cytoplasm of bacterial cells [98]
and has been shown to inhibit macromolecular synthesis of DNA,
RNA and proteins in E. coli and B. subtilis [99]. The increased antimi-
crobial activity of the LFchimera could therefore be attributed to com-
bined effect of the increased ability to disrupt bacterial membranes
which, in turn, provides entry into the cell and increases access to in-
tracellular targets. Collectively, these two modes of action would lead
to a substantial increase in the antimicrobial potency of the LFchi-
mera compared to either LFampB or LFcin17–30 on their own.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamem.2011.11.023
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